ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 288 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 0.47 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,315,233 | -18.1% | 48,948 | +8.6% | 0.00% | 0.0% |
| Q2 2023 | $1,606,768 | +27.0% | 45,058 | -9.5% | 0.00% | +100.0% |
| Q1 2023 | $1,265,301 | -48.7% | 49,815 | -18.1% | 0.00% | -66.7% |
| Q4 2022 | $2,467,468 | +18.5% | 60,835 | -3.5% | 0.00% | +50.0% |
| Q3 2022 | $2,083,000 | +19.1% | 63,019 | +26.9% | 0.00% | 0.0% |
| Q2 2022 | $1,749,000 | -8.0% | 49,669 | +7.4% | 0.00% | 0.0% |
| Q1 2022 | $1,901,000 | -21.7% | 46,247 | +26.2% | 0.00% | 0.0% |
| Q4 2021 | $2,429,000 | -2.7% | 36,637 | -8.4% | 0.00% | 0.0% |
| Q3 2021 | $2,497,000 | -30.4% | 39,998 | -7.7% | 0.00% | -33.3% |
| Q2 2021 | $3,590,000 | +11.9% | 43,343 | -10.4% | 0.00% | 0.0% |
| Q1 2021 | $3,207,000 | -18.5% | 48,359 | -5.7% | 0.00% | -25.0% |
| Q4 2020 | $3,936,000 | +70.0% | 51,301 | -4.6% | 0.00% | +33.3% |
| Q3 2020 | $2,315,000 | -20.4% | 53,760 | -20.1% | 0.00% | -25.0% |
| Q2 2020 | $2,908,000 | -23.4% | 67,323 | -49.0% | 0.00% | +33.3% |
| Q1 2020 | $3,798,000 | -10.4% | 131,986 | +97.4% | 0.00% | -40.0% |
| Q4 2019 | $4,241,000 | +47.4% | 66,863 | -34.5% | 0.01% | +25.0% |
| Q3 2019 | $2,878,000 | +4195.5% | 102,138 | +3964.4% | 0.00% | – |
| Q2 2019 | $67,000 | +45.7% | 2,513 | 0.0% | 0.00% | – |
| Q1 2019 | $46,000 | +48.4% | 2,513 | 0.0% | 0.00% | – |
| Q4 2018 | $31,000 | -45.6% | 2,513 | -16.0% | 0.00% | – |
| Q3 2018 | $57,000 | +62.9% | 2,992 | +15.1% | 0.00% | – |
| Q2 2018 | $35,000 | +34.6% | 2,599 | -27.8% | 0.00% | – |
| Q1 2018 | $26,000 | +100.0% | 3,599 | 0.0% | 0.00% | – |
| Q4 2017 | $13,000 | -18.8% | 3,599 | 0.0% | 0.00% | – |
| Q3 2017 | $16,000 | +166.7% | 3,599 | 0.0% | 0.00% | – |
| Q2 2017 | $6,000 | -14.3% | 3,599 | +1.8% | 0.00% | – |
| Q1 2017 | $7,000 | +40.0% | 3,537 | 0.0% | 0.00% | – |
| Q4 2016 | $5,000 | -80.0% | 3,537 | +5.9% | 0.00% | – |
| Q3 2016 | $25,000 | – | 3,340 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |